served in all major antigens, including env-encoded glycoproteins, and therefore are undistinguishable by current serological procedures (2, 11) . It has been shown (17, 21) that the transmembrane glycoprotein (TGP) (gp4l) of HIV-1 comprises an immunodominant domain located within a highly conserved region. Gnann et al. (8) have shown that the minimal epitope for immune recognition of the HIV-1 peptide is a seven-amino-acid sequence containing two essential cysteine residues linked by a disulfide bond. More recently, Norrby et al. (15) demonstrated the presence of a comparable immunodominant region within the TGP of SIV and introduced for the first time the possibility to distinguish serologically between HIV-1 and HIV-2 infections by using only oligopeptides from this antigenic domain. Subsequent data obtained in our laboratory showed a relatively high percentage of cross-reactivity with the described peptides, particularly with sera of African origin (3) . We proposed that the cross-reactivity might be due to conserved residues surrounding, both upstream and downstream, the typespecific sequences located within the two cysteines. Therefore, we synthesized shorter peptides to develop enzyme immunoassays allowing discrimination between HIV-1 and HIV-2 infections with maximal sensitivity and specificity. * [16] ) and one peptide corresponding to a sequence of SIVmaC (amino acids 610 to 619 of the envelope polyprotein, Mm142 strain [5] ) were prepared. The sequences are shown in Fig. 1 . Peptides HIV-1-TMSP10 and SIV-TMSP10 were made by the solidphase procedure developed by Merrifield (14) , on an automated peptide synthesizer (Applied Biosystems 431A) with tert-butyloxycarbonyl-protected amino acids and phenylacetamidomethyl resin. After synthesis, the resin support and the side chain-protecting groups were removed with the low-high trifluoromethanesulfonic acid procedure (18) by using p-cresol, dimethysulfide, and dithioethane as scavengers. After synthesis, the peptides were purified by reversephase chromatography using C8 columns (Aquapore octyl, 100 by 10 mm, 20 ,um; Applied Biosystems). As shown in Fig. 1 PBS/TW, 100 p,l of peroxidase-conjugated goat F(ab')2 antihuman immunoglobulin (TAGO, Burlingame, Calif.) diluted 1:10,000 in PBS/TW-newborn calf serum was incubated for 30 min at room temperature. After five washings in PBS/TW, the reaction was revealed by incubating a mixture of hydrogen peroxide-o-phenylenediamine for 10 min at room temperature. Color development was stopped with 2 N H2SO4, and the A492 was read. The cutoff value of every assay was calculated by using the mean optical density (OD) obtained with 105 HIV-negative sera. The mean values were 0.053, 0.052, and 0.068 for HIV-1-TMSP18, HIV-1-TMSP10, and SIV-TMSP10, respectively. All of the negative sera tested gave ODs below these mean values plus 4 standard deviations, except for one serum in the HIV-1-TMSP18 and the SIV-TMSP10 assays and two sera in the HIV-1-TMSP10 assay. The cutoff values were therefore estimated as the mean OD of the negative sera plus 4 standard deviations for every assay, i.e., 0.359, 0.363, and 0.378 for the HIV-1-TMSP18, HIV-1-TMSP10, and SIV-TMSP10 assays, respectively. The same negative control, an HIV-1 positive control, and an HIV-2 positive control were included in duplicate in every run that was then performed. The negative control serum gave ODs of 0.040 to 0.090 in different runs. Therefore, we estimated that the cutoff value could be calculated in each run as 0.300 plus the mean OD of the negative control.
Sera. A total of 235 serum samples were tested for the presence of antibody to the three peptides. The serotype specificities of the sera were previously assessed by Western blot analysis by using a procedure already described (4, 13) . Sera that were reactive to the envelope glycoproteins of HIV-1 were defined as HIV-1 positive. Sera that were reactive to the envelope glycoprotein of HIV-2 were defined as HIV-2 positive. Sera that were reactive to the envelope glycoproteins of both HIV-1 and HIV-2 were defined as doubly reactive (Fig. 2) . One hundred seventy-nine HIV-1-positive serum samples were collected from 71, 62, and 46 patients originating from France, Burundi (Central Africa) (1) , and the Ivory Coast (West Africa) (7), respectively. Forty-six serum samples were collected from HIV-2-in- fected patients. Ten doubly reactive serum samples were collected from residents of the Ivory Coast (7).
Inhibition procedure. Doubly reactive specimens were further tested for the ability to react with the peptides HIV-1-TMSP18 and SIV-TMSP10 in the presence of increasing concentrations of the homologous or heterologous peptide. In short, after the coating step, 50-,ul volumes of increasing amounts (0.01 to 8 ,ug) of peptides HIV-1-TMSP18 and SIV-TMSP10 (without the five N-terminal lysine residues) were added separately to the wells of both the HIV-1-TMSP18 and SIV-TMSP10 assays. Fifty-microliter serum samples diluted 1:10 in PBS/TW-newborn calf serum were then incubated in both assays at room temperature for 30 min in the presence of the homologous or heterologous peptide. The ensuing steps of the assay were done as described above. Therefore, each doubly reactive specimen was incubated with HIV-1-TMSP18 or SIV-TMSP10 before being tested with the HIV-1-TMSP18 and SIV-TMSP10 assays.
RESULTS
As shown in Table 1 absorbance values obtained in the HIV-1-TMSP18 and SIV-TMSP10 assays with 179 HIV-1-positive sera, 46 HIV-2-positive sera, 10 doubly reactive sera, and 105 negative sera is shown in Fig. 3 . All of the HIV-1-positive and HIV-2-positive sera except one gave absorbance values clearly above the cutoff. Only two sera positive for antibody to HIV-1 (1.1%) cross-reacted with the SIV peptide. These two specimens, from patients from the Ivory Coast, gave high absorbance values in the HIV-1-TMSP18 assay and low signals (0.426 and 0.393) in the heterologous SIV-TMSP10 assay. Only one serum positive for antibody to HIV-2 cross-reacted with the HIV-1 peptide. This serum, which was also weakly positive for antibody to HIV-1 glycoproteins gpi60 and gp4i by Western blot, was highly positive (OD, 1.638) in the SIV-TMSP10 assay, whereas it reacted weaker (OD, 0.583) in the HIV-1-TMSP18 assay.
Ten doubly reactive sera were tested with the HIV-1-TMSP18 and SIV-TMSP10 assays. One serum (Fig. 2 , sample J) was reactive only with the SIV-TMSP10 peptide (Fig. 3C) . The nine remaining sera reacted with both HIV-1-TMSP18 and SIV-TMSP10, with similar absorbance values (Fig. 3C) . The specificity of these doubly reactive sera was further assessed by using the inhibition assay. The results are summarized in Fig. 4 . Figure 4A shows the pattern of reactivity to HIV-1-TMSP18 and SIV-TMSP10 of a specimen positive only for antibody to HIV-1, in the presence of either soluble HIV-1-TMSP18 or SIV-TMSP10. The decrease of binding of antibody to HIV-1-TMSP18, shown by a decrease in OD, was directly related to the increase of soluble HIV-1-TMSP18 peptide in the reaction wells. In contrast, the increase of soluble SIV-TMSP10 peptide had no effect on antibody to HIV-1 binding to HIV-1-TMSP18. Similarly, Fig. 4B shows the pattern of reactivity to HIV-1-TMSP18 or SIV-TMSP10 of a specimen positive for antibody to HIV-2, in the presence of either soluble HIV-1-TMSP18 or SIV-TMSP10. The decrease of binding of HIV-2 antibody to SIV-TMSP10 was directly related to the increase of soluble SIV-TMSP10 peptide in the reaction wells, whereas the increase of soluble HIV-1-TMSP18 peptide had no effect on the binding of antibody to HIV-2 to solid-phase SIV-TMSP10. Figure 4C and D summarizes the two kinds of patterns observed with doubly reactive sera in the inhibition assay. The sample corresponding to Fig. 4D contained antibodies whose binding was neutralized in both the HIV-1-TMSP18 and SIV-TMSP10 assays only by the homologous peptide, as if the patterns in 4A and B had been superposed. This kind of inhibition pattern might argue for the presence of two distinct populations of antibodies following dual infection by HIV-1 and HIV-2. Among the nine sera that reacted with both HIV-1-TMSP18 and SIV-TMSP10 seven gave such an inhibition pattern. The remaining two sera gave inhibition patterns like that in Fig. 4C . The sample corresponding to Fig. 4C contained antibodies that were neutralized by soluble HIV-1-TMSP18 peptide in the HIV-1-TMSP18 assay like a single HIV-1-positive serum. In contrast, the binding of antibodies present in this sample to SIV-TMSP10 was nonspecifically inhibited by both homologous and heterologous peptides, even at a low concentration. This kind of data might argue for the presence of antibody to HIV-1 that strongly crossreacted with HIV-2. These two sera could have been collected from HIV-1-infected patients and cross-reacted strongly with HIV-2 envelope sequences. seven-amino-acid sequence containing two cysteine residues (amino acids 603 to 609, lymphadenopathy-associated virus strain Bru [20] ). Moreover, it appeared that the presence of both cysteine residues was essential for the antigenic conformation of the epitope via formation of disulfide bonds. In the present study, we confirm the usefulness of the two cysteine residues in the sequence of the HIV-1 peptide, since 100% of the HIV-1-positive sera bound to HIV-1-TMSP18 (DQLLGIWGCSGKLICTTA), whereas only 51% of them reacted with a shorter peptide, HIV-1-TMSP10 (kkkkkGl WGCSGKLI), which did not include the C-terminal cysteine residue. Gnann et al. have synthesized a peptide whose C-terminal cysteine was substituted with a serine residue (LGLWGCSKLIS) and showed that only 9% of HIV-1-positive sera reacted with this peptide. We also found that removal of the C-terminal cysteine dramaticaly reduced the antigenicity of this HIV-1 epitope, although approximately half of our HIV-1 positive sera were able to bind the peptide lacking this cysteine. This difference might be due to the presence in our peptide of the N-terminal lysine residues that would increase both accessibility to antibodies and binding of peptides to the solid phase.
In contrast to the HIV-1 data, our results clearly indicate that the C-terminal cysteine is not essential for the antigenic conformation of the SIV peptide, since 100% of the HIV-2-positive sera bound to SIV-TMSP10. Previous data (not shown) indicated that approximately 80% of HIV-2-positive sera bound to lysine-free SIV-TMSP10. This means not only that good reactivity with the SIV peptide is due to the five N-terminal lysine residues but also that this chemical modification greatly enhances binding of the antibodies.
Our data show that the immunodominant epitope located on the TGPs of HIV-1 and HIV-2-SIVmac do not involve exactly the same conserved amino acids, especially the C-terminal cysteine residue. Although an important conformational conservation between the TGPs of the two virus types has been reported (9), minor amino acid changes would be sufficient to shift the position of the epitopes slightly. For instance, there are three cysteine residues in the TGP of HIV-1 instead of the four cysteine residues in the TGP of HIV-2. This difference could explain the modification of the conformation and therefore the immune recognition of the TGP during natural infection.
The immunoassays using HIV-1-TMSP18 and SIV-TMSP10 were able to discriminate clearly between HIV-1 and HIV-2 infections at least as efficiently as the Western blot assay. Immunoassays using such short peptides, in which the conserved residues located on both sides of the antibody-binding site are not included, could abolish almost all of the envelope cross-reactivities observed in Western blot assays (19) . Our study also shows that HIV-1-TMSP18 and SIV-TMSP10 assays can be more informative than Western blotting with doubly reactive sera.
Most of the countries in which HIV-1 and HIV-2 are both prevalent are economically poor. In such countries, a sensitive assay able to detect both viruses is essential for screening purposes. Peptide enzyme immunoassays such as the prototypes discussed in the present study are alternative procedures that must be evaluated prospectively for confirmation and serotyping. They may offer diagnostic algorithms which could limit the use of expensive Western blots.
